Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.51 | -0.24 | 0.31 | 0.00 |
| FCF Yield | -3.84% | -3.64% | 6.46% | 5.08% |
| EV / EBITDA | 18.61 | 7.93 | 4.38 | 6.64 |
| Quality | ||||
| ROIC | -0.23% | 5.82% | 17.66% | 19.02% |
| Gross Margin | 6.28% | 22.67% | 42.54% | 41.19% |
| Cash Conversion Ratio | -6.61 | 0.06 | 0.69 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.13% | -4.04% | 35.33% | 18.72% |
| Free Cash Flow Growth | 13.38% | -143.82% | 16.86% | 750.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | -0.60 | -0.51 | -0.08 |
| Interest Coverage | -0.92 | 53.84 | 86.12 | 45.42 |
| Efficiency | ||||
| Inventory Turnover | 1.76 | 1.55 | 3.61 | 6.44 |
| Cash Conversion Cycle | 199.58 | 219.86 | 81.56 | 45.36 |